Search research articles
Contact Us
Filters
Showing results (11-20 of 18) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 18 results.
Integrative Cancer Therapies
|
January 1, 2009
Enzymes, trophoblasts, and cancer: the afterlife of an idea (1924-2008)
Ralph W Moss
Lancet (London, England)
|
April 9, 2002
Preoperative and postoperative radiotherapy and survival in colorectal cancer
Ralph W Moss
Pharmacological Research
|
November 9, 2013
Control of minimal residual cancer by low dose ipilimumab activating autologous anti-tumor immunity
Shimon Slavin, Ralph W Moss, Tibor Bakacs
Immunobiology
|
August 9, 2011
Ipilimumab (Yervoy) and the TGN1412 catastrophe
Tibor Bakacs, Jitendra N Mehrishi, Ralph W Moss
Pharmacological Research
|
April 17, 2012
Interesting possibilities to improve the safety and efficacy of ipilimumab (Yervoy)
Tibor Bakacs, Jitendra N Mehrishi, Miklós Szabó, et al.
Cancer Immunology, Immunotherapy : CII
|
March 11, 2020
Significant association between tumor mutational burden and immune-related adverse events during immune checkpoint inhibition therapies
Csaba Kerepesi, Tibor Bakacs, Ralph W Moss, et al.
Integrative Cancer Therapies
|
October 10, 2009
Sonodynamic and photodynamic therapy in advanced breast carcinoma: a report of 3 cases
Xiaohuai Wang, Weimin Zhang, Zhiyong Xu, et al.
Scandinavian Journal of Immunology
|
October 8, 2019
Exploiting autoimmunity unleashed by low-dose immune checkpoint blockade to treat advanced cancer
Tibor Bakacs, Ralph W Moss, Ralf Kleef, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 18) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 18 results.
Integrative Cancer Therapies
|
January 1, 2009
Enzymes, trophoblasts, and cancer: the afterlife of an idea (1924-2008)
Ralph W Moss
Lancet (London, England)
|
April 9, 2002
Preoperative and postoperative radiotherapy and survival in colorectal cancer
Ralph W Moss
Pharmacological Research
|
November 9, 2013
Control of minimal residual cancer by low dose ipilimumab activating autologous anti-tumor immunity
Shimon Slavin, Ralph W Moss, Tibor Bakacs
Immunobiology
|
August 9, 2011
Ipilimumab (Yervoy) and the TGN1412 catastrophe
Tibor Bakacs, Jitendra N Mehrishi, Ralph W Moss
Pharmacological Research
|
April 17, 2012
Interesting possibilities to improve the safety and efficacy of ipilimumab (Yervoy)
Tibor Bakacs, Jitendra N Mehrishi, Miklós Szabó, et al.
Cancer Immunology, Immunotherapy : CII
|
March 11, 2020
Significant association between tumor mutational burden and immune-related adverse events during immune checkpoint inhibition therapies
Csaba Kerepesi, Tibor Bakacs, Ralph W Moss, et al.
Integrative Cancer Therapies
|
October 10, 2009
Sonodynamic and photodynamic therapy in advanced breast carcinoma: a report of 3 cases
Xiaohuai Wang, Weimin Zhang, Zhiyong Xu, et al.
Scandinavian Journal of Immunology
|
October 8, 2019
Exploiting autoimmunity unleashed by low-dose immune checkpoint blockade to treat advanced cancer
Tibor Bakacs, Ralph W Moss, Ralf Kleef, et al.
Page
of 2